Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting
Salvatore Del Prete(Federico II University Hospital), Michele Orditura(University of Campania "Luigi Vanvitelli"), Carlo Buonerba(CTO Andrea Alesini), Liliana Montella(Ospedale Santa Maria), Grazia Arpino(University of Naples Federico II), Maria Aliberti, Clementina Savastano, Antonio Febbraro(Fatebenefratelli Hospital), Olga Fiorentino, Sabino De Placido, Giuseppe Colantuoni(Azienda Ospedaliera S.Giuseppe Moscati), Giuseppe Buono(Federico II University Hospital), Pasquale Dolce, Angela Ruggiero(National Institutes of Health), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 11
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Treatment of gastric cancer
|World Journal of Gastroenterology|2014|628
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
The Signature of Maternal Rearing in the Methylome in Rhesus Macaque Prefrontal Cortex and T Cells
|Journal of Neuroscience|2012|312